Hypoglycemia: what is it for the neonate?

Area of Science:

• Neonatal Medicine
• Pediatric Endocrinology
• Clinical Biochemistry

Background:

• The definition of hypoglycemia in newborn infants lacks consensus due to inconsistent correlations between glucose levels, symptoms, and long-term outcomes.
• Establishing clear plasma glucose thresholds is crucial for timely intervention to prevent potential neurological damage in neonates.

Purpose of the Study:

• To review and define evidence-based plasma glucose threshold values for monitoring and intervention in newborn infants with hypoglycemia.
• To differentiate between thresholds for surveillance/intervention and target therapeutic glucose levels.

Main Methods:

• Systematic review of available data on plasma glucose concentrations in newborn infants.
• Analysis of clinical symptoms and risk factors associated with hypoglycemia.
• Comparison of proposed thresholds with existing guidelines and therapeutic targets.

Main Results:

• For clinically symptomatic infants, a plasma glucose threshold of ≤45 mg/dL (2.5 mmol/L) warrants intervention.
• For asymptomatic or at-risk infants, regardless of age, a plasma glucose threshold of <36 mg/dL (2.0 mmol/L) indicates the need for close monitoring.
• Specific considerations for variations, such as in breast-fed infants, are discussed.

Conclusions:

• The proposed thresholds provide a framework for managing neonatal hypoglycemia, aiming to mitigate neurological risks.
• Intervention thresholds should be distinct from target therapeutic glucose ranges, which are recommended between 72-90 mg/dL (4-5 mmol/L).
• Standardized definitions and thresholds are essential for consistent clinical practice and improved neonatal outcomes.